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Abstract
Backround Visual analogue scales (VAS) are psycho-
metric measuring instruments designed to document
the characteristics of disease-related symptom sever-
ity in individual patients and use this to achieve a
rapid (statistically measurable and reproducible) clas-
sification of symptom severity and disease control.
VAS can also be used in routine patient history taking
and to monitor the course of a chronic disease such
as allergic rhinitis (AR). More specifically, the VAS has
been used to assess effectiveness of AR therapy in real
life, both in intermittent and persistent disease.
Methods This position paper takes a detailed look at
the historical development of VAS and its method-
specific principles. Particular focus is put on aspects
of practical application in daily routine and on a criti-
cal discussion of the advantages and disadvantages of
the individual methods.
Results VAS are well validated for the measurement of
AR symptoms and correlate well with the ARIA (aller-
gic rhinitis and its impact on asthma) severity classifi-
cation and also correlated well with rTNSS and RQLQ.
Moreover, several treatment studies on AR have used
VAS as an evaluation parameter. Thanks to the use
of new (real-life and real-time) communication tech-
nologies, such as smartphone apps, Discussion: VAS
can be used relatively simply and highly effectively to
assess disease control. The VAS lends itself very well
to digitization and has now been incorporated into
a smartphone app (called Allergy Diary) to assess AR
control and direct treatment decisions as part of an AR
clinical decision support system (CDSS). MASK Rhini-
tis has developed this app, which is currently available
in 15 different languages.




ARIA Allergic rhinitis and its impact on asthma
MACVIA MACVIA-ARIA sentinel network
QoL Quality of life
RQLQ Rhinoconjunctivitis quality of life ques-
tionnaire
VAS Visual analogue scales
Introduction
A detailed and thorough patient history combined
with a physical examination of the patient while
taking the reported symptoms into particular consid-
eration form the focus of allergy diagnostics. When
monitoring allergic rhinitis (AR), patient history in
terms of the time, location, and situation in which
symptoms occur plays an equally important role and
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should be supported by means of measuring parame-
ters aimed at a semi-quantitative—or as quantitative
as possible—rating of symptom severity and type.
The diagnosis of AR is established if two or more
of the following symptoms have been identified using
appropriate tests: nasal obstruction, secretion, sneez-
ing, or nasal itching lasting for more than 1 h/day for
more than 2 weeks/year, as well as an allergen-medi-
ated cause of these symptoms [31, 32]. The type and
severity of individual symptoms can vary from patient
to patient and therapy should aim at total symptom
control. Furthermore, it is essential in AR treatment
monitoring to obtain reliable and comparable infor-
mation relating to symptom severity before, during,
and after treatment.
In order to document and evaluate these type of
data, it is important that answers are not expressed
in an arbitrary manner, but rather that they are as-
signed to a statistically documentable category. Such
a categorization must enable both an intra- and in-
terindividual comparison of AR symptom severity.
To date, categorical scales have predominantly been
used—primarily in controlled studies—to evaluate
the efficacy of AR treatments, such as drug therapies
and allergen-specific immunotherapy [1, 2].
However, these are poorly suited to daily routine,
since they are prone to misinterpretation. Untrained
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test subjects do not use categories in four- to seven-
level categorical scales as equally broad: the response
options in the central categories are considered to be
almost twice as broad (i. e., applicable) as the two
outlying extremes. Thus, the linear assumption of
equally broad categories only applies to the middle
categories [3] and means that in a categorical scale
users are much more likely to choose the middle cate-
gories. This bias can only be compensated by system-
atic training, which is unaffordable in routine patient
care.
An AR VAS can represent a helpful alternative in this
situation, since it is seen by test subjects as a con-
tinuum in which the same differences in symptom
strength are assigned the same intervals on the VAS
scale. Therefore, VAS is particularly suited for use in
every day practice (by both patients and healthcare
providers) since it is simple and intuitive to use (re-
quiring no training), reproducible, sensitive, and suit-
able for everyday use.
Thus, particularly when combined with modern
communication technologies such as the use of
a smartphone app, a VAS can represent a valuable
tool to document AR symptom severity and symptom
control and can thus monitor treatment.
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Psychometric measurement instruments
In general, endpoints, at the very least, are assigned
a verbal descriptor in psychometric scales to docu-
ment subjectively perceived symptoms; this can po-
tentially apply to each response category proposed in
categorical scales. Scales need to be exhaustive in
order to ensure that the entire spectrum of possible
responses can be found between the endpoints.
In order to demonstrate that patients have the en-
tire range of possible perceptions of symptoms at their
disposal when responding, each end of the scale is de-
fined with contrasting terms such as “always – never”,
“applies completely – does not apply at all”, or “yes
– no”. One end of the scale represents the maximum
conceivable symptom strength (i. e., 100%), the other
end no symptoms whatsoever (i. e., 0%).
Visual analogue scales
Visual analogue scales (VAS) are psychometric re-
sponse scales used to measure subjective character-
istics or attitudes and have been used in the past for
a multitude of disorders, as well as in market research
and social science investigations, among others [3, 4].
VAS were first described in 1921 and referred to at
the time as a “graphic rating method” [5]. The initial
publication, which covered no more than one page,
was presented as a new method for management
personnel to evaluate the workers assigned to them
[3].
Until the 1940s, only a handful of sociomedical and
psychological publications addressed the topic of VAS.
It was not until the 1960s that the literature showed
rekindled interest in the use and study of VAS [3, 6].
The word “visual” in the term visual analogue scale
emphasizes the concrete nature of this type of scale
(straight line), in contrast to abstract, non-repre-
sentable evaluation scales (“. . . I don’t feel well . . . ”).
The word “analogue” stresses the infinitely vari-
able, continuously changing response format. As a re-
sult, and particularly since the advent of computer
technology, a verbal distinction to “digital” is made,
whereby there is always a stepwise change per Bit.
VAS are, therefore, effectively classless, meaning
that, theoretically, they permit an infinite number of
gradations between endpoints—the variable is a latent
continuum [7].
Thus, they clearly differ from (in the above sense,
digital) categorical scales, which do not permit inter-
mediate evaluations, and, in extreme cases, provide
only two modalities (“yes” – “no”) [3].
VAS scores may also be classified retrospectively, by
forming value groups. So for example in an Allergy Di-
ary APP—those with VAS > 5 = uncontrolled AR, VAS
2–5 = partly controlled AR and VAS score < 2 = well-
controlled AR. The process of linear category reduc-
tion, for example, may find application to this end
[8].
One of the major advantages of VAS is that they are
perceived as a continuum, meaning that their data
are considered interval-scaled. Two equally sized in-
tervals on a VAS are always interpreted as two equally
sized differences by respondents. This makes it possi-
ble to calculate the arithmetic mean.
Data obtained from categorical scales, on the other
hand, can only be interpreted in terms of their dissim-
ilarity and rank; as such, the data are ordinal-scaled.
Although the categories reflect a hierarchy, no state-
ment can be made on how large the differences be-
tween the individual categories are for a respondent.
Therefore, here it is only permissible to give median
values.
Practical application of visual analogue scales for
AR
A VAS is usually a 100-mm long horizontal line with
verbal descriptors (word anchors) at each end to ex-
press the extremes of the feeling. AR patients mark the
point on the line that best corresponds to their symp-
tom severity or AR control status. To this end, they
are instructed to put a cross on the straight line at the
point that most accurately expresses their degree of
agreement.
When reading the VAS, the position of the respon-
dent’s cross is generally assigned a score between 0
and 100. If documented in paper form, the scores
can then be simply transferred to a 100-value scale
using a millimeter tape measure. The division into
hundredths is considered sufficiently sensitive [6].
When using electronic documentation options,
analysis is usually performed in an automated man-
ner by a programmed algorithm.
It is important to bear in mind when selecting ver-
bal anchors that these are intended to verbalize the
extremes in such a way that the entire spectrum of
possible degrees is covered, and not only a part thereof
[3, 4]. Thanks to the continuous response format, the
patient is not restricted to a fixed number of poten-
tial responses, but instead the responses move along
a continuum, a seamlessly coherent gradation.
The AR symptoms as a whole, as well as each symp-
tom individually (e. g., nasal obstruction, rhinorrhea,
itch, sneezing), can be evaluated on a separate VAS
as well as the impact of AR on asthma for comorbid
patients.
VAS should not have any markings (e. g., identifying
the middle or dividing the line up into equally sized
fragments), since the sensitivity of VAS without mark-
ings is higher than it is with [9]. The most important
aspect of any VAS however is the question that is com-
bined to it and not the line. The line remains the same
but the question may change.
Numerous studies have shown that the respondent
is guided by the principle of equisection, the cognitive
subdivision into equal intervals [3, 4, 10]. As part of
this, most users proceed in such a way that they first
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rate the scale endpoints that are clearly described by
the verbal descriptors and which delimit the range de-
scribed by the VAS. The middle of the scale, which is
easily identified even without marking, is then rated.
From the middle of the VAS line, it is possible to de-
termine the respective midpoints to the two extremes,
such that one can already identify five points (0, ¼, ½,
¾, 1). Working from these points, further differentia-
tions are then made (by the user), so that the VAS can
be sufficiently well divided without significant cogni-
tive effort [10, 11]. Interestingly, methodological stud-
ies on the use of VAS showed a comparable approach
among the majority of VAS users [3, 4, 10, 11].
Methods to construct equidistant, nonverbal cate-
gory labels using VAS have been increasingly used re-
cently, e. g., rating scales that use smilies as symbolic
markings and verbal anchors [12].
VAS are used in most studies for individual compar-
isons, i. e., repeat measurements at different points in
time, and as part of treatment monitoring [4].
Advantages of visual analogue scales
The first detailed list of the advantages and disadvan-
tages of VAS was published only 2 years after the con-
cept was first described [13]. Although the findings in
that article have been deepened and expanded upon,
they still apply today given the general nature of the
findings.
Perhaps the most obvious advantage of VAS is that
they offer an extremely high degree of resolution and
hence the option of very fine nuances of judgment [4,
5, 14]. The respondent is not bound in a potentially
overly tight corset of predefined categories and, as
a result, is able to express themselvesmore freely. That
is arguably also the reason why individuals whose at-
titude lies between two categories prefer this type of
scale [6, 8, 15]. Repeat measurements may indicate
even minute changes [16, 17], which are neverthe-
less perceived by patients as already highly relevant
in some cases [4]. The high degree of detail in VAS
is, above all, an advantage in the case of items with
low variance and permits rank-based tests to be used
effectively. In the case of low-variance items, many
cases fall into one category—hereby making them in-
distinguishable from one another—and are given the
same position in the ranking. With VAS, even those
cases that are extremely similar can be distinguished
from one another [8]. The variation in significance of
identical intervals on the VAS as interpreted by dif-
ferent users is thus smaller compared with categori-
cal scales in which the values of individual categories
fluctuate more among different users [8].
Moreover, from a subjective perspective, those
tasked with processing the scales like using VAS, the
main reason for this being their easy handling and
decision-making [18]. Thus, it would appear that
VAS are particularly well suited to routine treatment
and have a positive effect on data quality. According
to one study, VAS can have a moderating effect on
socially desirable response behavior, since it is more
difficult to estimate which value is expected on the
scale continuum [8]. Thus, the values on VAS should
be closer to the true attitudes of respondents com-
pared with values obtained with categorical scales.
Although, as with other types of scales, halo effects
have been observed with VAS—a trend towards the
middle was seen in particular when several items
were to be evaluated—these were distinctly smaller
than in categorical scales [16].
VAS permit statistically significant differences in
distributions to be readily determined [6]. This type
of scale is considered to be more accurate and sensi-
tive and subject to less distortion and bias compared
with categorical scales [19].
VAS are particularly well suited to measuring con-
tinuous features [20], as AR symptoms inherently are,
since their continuous nature correspondsmore to the
score to be measured than is the case in graded cat-
egorical scales. This advantage with VAS proves to
be true with other, entirely different subjective phe-
nomenon, such as measuring mood, pain, and emo-
tions [21]. A large number of studies have confirmed
the reliability and validity of VAS measurements [6,
16, 22–27]. Data obtained with VAS can be converted
parametrically to an interval-scale level [20].
Another advantage of VAS becomes apparent when
one uses statistical test methods based on ranks for
analysis. The ranks of items can be readily determined
and the high data resolution results in a large num-
ber of possible ranks. The question of whether an
odd or an even number of categories should be speci-
fied when constructing a response scale does not arise
with VAS [3]. VAS data not only permit a more differ-
entiated analysis of the middle categories, they also
indicate slight tendencies in one direction. The prob-
lem whereby even respondents with average attitudes
are forced to move towards an extreme no longer ex-
ists [3, 28].
Disadvantages of visual analogue scales
The main practical disadvantage of VAS is that they
require subsequent distance measurements [29]. This
involves considerable effort in terms of data entry for
statistical analysis, as well as high costs. However,
electronic data entry (e. g., using a smartphone) gets
around this problem. Furthermore, VAS can only be
used in written (or digital) format and not for oral in-
terviews. A minimum patient ability in terms of visual
ability and hand-eye coordination is required in VAS
[4].
One drawback encountered with VAS is that pa-
tients have difficulty finding the point on the line
that best applies to them, i. e., weighing up the sig-
nificance a distance from the verbal anchor has [14,
19]. This is the downside of dispensing with limiting
categories. Although using VAS enables patients to
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make finely graded assessments, this can have neg-
ative effects if questions are unclear or patients feel
ambivalent, given that clues on how to formulate an
assessment are lacking.
Similar difficulties may be encountered when in-
terpreting VAS scores. While it is easier to meaning-
fully interpret a modest number of categories, and
verbal descriptors can be assigned to the respective
categories, the interpretation of (raw) VAS scores is
less clear. However, the question of the score from
which a change on the VAS scale is to be considered
clinically relevant and not seen simply as a random
variation has now been well answered (see below).
Visual analogue scales as a measurement
instrument in allergic rhinitis
Objective methods to measure nasal obstruction in-
clude inspiratory peak flowmetry, acoustic rhinom-
etry, and anterior rhinomanometry [30]. AR-specific
as well as generic quality of life (QoL) questionnaires,
with some including multiple items [33, 34], have
been developed to assess QoL [31, 32].
These and other measuring instruments are un-
doubtedly suited to posing questions about the rel-
evant parameters. However, around 80–90% of AR pa-
tients are cared for by their general practitioner and/or
pharmacist or practice self-medication.
Thus, it would appear important to use a simple
parameter that reacts readily to changes and that can
be applied in different situations and at various levels
of care. VAS are well suited for AR patient self-assess-
ment both in specialist and general medical treatment
[35, 36], as well as for treatment assessment by phar-
macists [37]. Although VAS scores in AR do not differ
significantly in terms of sensitivity and reproducibility
from other psychometric tests using categorical scales
[33, 38–43], they have proved to be superior in a num-
ber of studies in terms of user friendliness and better
resolution of scores [21, 44].
Precisely because even very small changes are ap-
parent with VAS, and these are sometimes more chal-
lenging to interpret compared with jumps on cate-
gorical scales, it is important to define the magnitude
from which changes are considered relevant. There
are extensive data on this for AR.
In most studies, a VAS of 50 (on a 100-mm scale) in-
dicates moderate to severe AR [45–47]. Another study
set the threshold at 60mm [48]. Furthermore, VAS
correlate well with the ARIA classification [39, 42, 43].
It was also noted that VAS scores that improved to be-
low 50mm as a result of treatment correlated well with
a normalized rhinoconjunctivitis QoL questionnaire
(RQLQ) and work productivity and activity impair-
ment questionnaire: allergy specific (WPAI-AS) [38],
whereas patients whose VAS remained above 50mm
continued to exhibit pathological scores in terms of
QoL and work productivity [38].
It was shown for AR that, irrespective of the base-
line VAS score, an improvement of 23mm under ther-
apy indicated effective treatment [49]; moreover, an
improvement of 30mm was always associated with
improvements in QoL parameters [35, 49]. MACVIA
ARIA defined AR control cut-offs are [35, 49]:
● >50: uncontrolled,
● 20–50: partly controlled,
● <20: well controlled.
Patients on placebo treatment, on the other hand,
showed improvements of only 10mm VAS in some
studies [50, 51].
VAS were also used as an evaluation parameter in
double-blind, placebo-controlled studies [50–56]. In
two large AR studies to evaluate treatment outcomes
with antihistamines, VAS were better able to discrim-
inate between placebo- and verum-treated patients
than could the total symptom score [50, 51].
VAS have also been successfully used in real-life and
observational studies [52, 57, 58].
It was shown that VAS for AR can be used in all age
groups—including preschool children (with supervi-
sion) [59], as well as elderly patients [60].
VAS have also been evaluated in numerous lan-
guages (e. g., German, French, English, Spanish, and
Japanese) [43, 48, 50, 51, 60–63].
Electronic collection of VAS data in AR
When a paper-based format is used, VAS readings
(measuring the score with a ruler) takes up the great-
est amount of time in terms of data analysis [3]. This
time expenditure is dispensed with by means of au-
tomatically programmed analysis of online data, e. g.,
in the context of an app.
The project group “MASK-Rhinitis” (MACVIA-ARIA
Sentinel network) has developed a free smartphone
app for patients called Allergy Diary and is currently
developing a companion tablet-based app for health-
care providers (Allergy Diary Companion), both of
which use a digitized VAS (Fig. 1; [58–60]). Daily
symptom assessments are recorded in the MACVIA-
ARIA app using a simple VAS, and VAS scores catego-
rized as the degree of AR control. As recommended
the VAS used is a simple line, with no incremen-
tal lines, with simple word anchors at either end.
The question is “overall how much are your aller-
gic symptoms bothering you today” from “not at all
bothersome” to “extremely bothersome”.
The assessment scale is a VAS with the verbal an-
chors “not impairing” and “highly impairing” (sepa-
rately for nose, eye, and asthma symptoms), which
only need to be tapped in order to answer the ques-
tions. The app users are also asked to enter their daily
medications they use. A reminder function helps pa-
tients to record symptoms regularly and to take their
recommended treatment. Symptom assessments and
drug requirements can be updated over the course of
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Fig. 1 Practical applicationof visual analoguescales (VAS) in
theMACVIA-ARIAapp. (Usershave to answer to thequestion
indicated. When theuser touches the indicated line, amarker
bar appears. Themarker bar canbemovedbackwardsand for-
wardswithafingerandplacedattheappropriatepoint.Oncethe
appropriatepoint on the linehasbeen found, theuser presses
“Next” inorder to proceed to thenextVAS. EachVASneeds to
becompletedoncedaily)
the day. Results (including those for longer time peri-
ods) are shown in graph form.
The aim of this app is to achieve rapid and sus-
tained AR control and to make this measurable. This
is intended to improve physician–patient communi-
cation. If a user records VAS scores indicative of poor
AR control for 3 or more consecutive days, the app
suggests that they seek medical advice.
Jean Bousquet et al. have tested and evaluated use
of the app in real life, and the data obtained using the
app, in a feasibility study. To this end, the data from
the first 730 allergy diary users were tested.
Analysis of the results attested to the app’s high user
friendliness, since all participants had answered the
basic questions correctly. Furthermore, it was possible
to identify simple phenotypical characteristics based
on the app that helped rate rhinitis. For example, daily
impairments, as well as impairments in working life,
in patients with rhinorrhea appeared to be more pro-
nounced the higher the number of symptoms noted
by the user in the allergy diary app. However, the au-
thors of the study concluded that their results need
to be supported by the analysis of larger volumes of
data obtained using the app (more app users), as well
as further investigations. Also, it is not yet possible
for the treating physician to evaluate the data, and
possible patient concerns (e. g., data protection, cen-
tral data collection, and commercialization) need to
be discussed and resolved in the long term.
The Allergy Diary app is currently available in 15
different languages and can be downloaded for free in
the Google Play Store and the Apple App Store. Sim-
ilar electronic VAS diaries have already been used in
numerous randomized, controlled studies [50, 51].
Conclusion
A VAS represents a useful alternative to other psycho-
metric scales for the documentation of AR symptoms
and assessment of AR control.
A VAS is particularly suited to documenting AR
symptom severity and disease control in routine treat-
ment by virtue of its simplicity, time-saving handling
and low susceptibility to errors. Since the VAS is seen
by the patient as a continuum, the same differences
in symptom severities are assigned the same intervals
on the VAS.
Thus, particularly when combined with modern
communication technologies such as a smartphone
app, a VAS is a valuable tool for the documentation
of symptom severity, treatment effectiveness, and
disease control in AR.
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